📣ESMO #ClinicalPracticeGuideline Express Update on #PancreaticCancer: updated 1st- & #2nd-line treatment recommendations for managing #MetastaticPancreaticCancer, following approval of 1st-line nanoliposomal #irinotecan. #ESMOGuidelines

🔗https://buff.ly/Mybc2Nq

@ducreuxmichel.bsky.social

Mitazalimab shows promising survival rates in cancer study - PharmaTimes Updated data from phase 2 study reveals survival benefit

#oncology #Mitazalimab #survivalrates #phase2study #survivalbenefit #AlligatorBioscience #phase2clincialtrial #OPTIMIZE1study #combinationtherapy #mFOLFIRINOX #metastaticpancreaticcancer #pancreaticcancer #pancreaticcancerpatients #clinicaltrials #drugdevelopment
pharmatimes.com/news/mitazal...